Evidence map›Paper›PMID 41000703›Full record

ArticlebioRxiv : the preprint server for biology2025

Structural and Mechanistic Basis for Antibody Neutralization of the Measles Fusion Protein.

Dawid S Zyla, Roberta Della Marca, Davide Lacarbonara, Gele Niemeyer, Gillian Zipursky, Laura Di Clemente, Gabriella Jonathan-Trakht, Gavreel Kalantarov, Marissa Acciani, Giulia Laterza and 7 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors.

Dawid S ZylaCenter for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, California, USA.ORCID 0000-0001-8471-469X
Roberta Della MarcaCenter for Host-Pathogen Interaction, Columbia University Vagelos College of Physicians and Surgeons, New York, New York, USA.
Davide LacarbonaraCenter for Host-Pathogen Interaction, Columbia University Vagelos College of Physicians and Surgeons, New York, New York, USA.
Gele NiemeyerCenter for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, California, USA.
Gillian ZipurskyCenter for Host-Pathogen Interaction, Columbia University Vagelos College of Physicians and Surgeons, New York, New York, USA.
Laura Di ClementeCenter for Host-Pathogen Interaction, Columbia University Vagelos College of Physicians and Surgeons, New York, New York, USA.
Gabriella Jonathan-TrakhtDepartment of Medicine, Columbia University Vagelos College of Physicians and Surgeons, New York, New York, USA.
Gavreel KalantarovDepartment of Medicine, Columbia University Vagelos College of Physicians and Surgeons, New York, New York, USA.
Marissa AccianiCenter for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, California, USA.
Giulia LaterzaCenter for Host-Pathogen Interaction, Columbia University Vagelos College of Physicians and Surgeons, New York, New York, USA.
Dariia VyshenskaDepartment of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, USA.
Kathryn M HastieCenter for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, California, USA.
Branka HorvatImmunobiology of Viral Infections, CIRI, International Center for Infectiology Research, INSERM U1111, CNRS UMR5308, University Lyon 1, ENS de Lyon, Lyon, France.
Alexander L GreningerDepartment of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, USA.ORCID 0000-0002-7443-0527
Stefan NiewieskDepartment of Veterinary Biosciences, College of Veterinary Medicine, The Ohio State University, Columbus, Ohio, USA.
Erica Ollmann SaphireCenter for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, California, USA.
Matteo PorottoCenter for Host-Pathogen Interaction, Columbia University Vagelos College of Physicians and Surgeons, New York, New York, USA.ORCID 0000-0003-3866-9220

Funding

Vaccines and Therapeutic Antibodies to Respiro, Rubula, Peribunya and Phenuiviridae (R2P2)-ReVAMPPU19AI181984 · NIAID · WASHINGTON UNIVERSITY · PI MOSCONA, ANNE, RAPPUOLI, RINO · 2024 to 2024
$44.1M
Mechanistic Virology CoreU19AI109762 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI SAPHIRE, ERICA OLLMANN · 2014 to 2018
$29.6M
ChimeraX -- Next Generation Visualization and Analysis Software for Multiscale ModelingR01GM129325 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI FERRIN, THOMAS E · 2018 to 2025
$5.2M
Design of fusion inhibitors to block measles host-to-host infectionR01AI176833 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Matteo Porotto · 2023 to 2026
$2.8M
Mechanisms of measles virus CNS adaptationR01NS091263 · NINDS · WEILL MEDICAL COLL OF CORNELL UNIV · PI POROTTO, MATTEO · 2015 to 2019
$1.9M
Development of therapeutic fusion inhibitor peptides for Measles encephalitisR01NS105699 · NINDS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI POROTTO, MATTEO · 2018 to 2022
$1.8M
Thermostable measles fusion glycoprotein as a new vaccine strategyR56AI183536 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI POROTTO, MATTEO, SAPHIRE, ERICA OLLMANN · 2024 to 2024
$884k
What is the human antibody response to measles virus vaccination?R21AI180456 · NIAID · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI SAPHIRE, ERICA OLLMANN · 2024 to 2025
$496k
NIAID NIH HHS R01 AI176833NIAID NIH HHS R21 AI180456NIAID NIH HHS R56 AI183536NIAID NIH HHS U19 AI109762NIAID NIH HHS U19 AI181984NIGMS NIH HHS R01 GM129325NINDS NIH HHS R01 NS091263NINDS NIH HHS R01 NS105699
6 · The paper itself

Abstract

Measles virus (MeV) is a highly contagious viral pathogen and remains a major global health threat. Resurgent infections, driven by insufficient vaccine coverage, waning herd immunity, and the vulnerability of immunocompromised individuals, highlight the urgent need for effective countermeasures. Monoclonal antibodies (mAbs) represent a promising strategy, both as antiviral agents and as probes of viral entry mechanisms. While most vaccine-elicited neutralizing antibodies target the hemagglutinin (H) protein, emerging evidence suggests that antibodies against the fusion (F) protein are also potent inhibitors. Still, there is insufficient information on the target sites and activities of antibodies against the F protein. Like other class I fusion proteins, MeV F exists in a metastable prefusion state that undergoes dramatic conformational changes during viral entry. Here, we selected four mAbs that recognize conformational patterns of F-prefusion and/or postfusion, characterized their epitopes, specificities, and antiviral activities. Structural analyses mapped antibody interactions onto pre- and postfusion F conformations, revealing that all three neutralizing mAbs are specific for the prefusion form, while the non-neutralizing mAb recognizes only the postfusion F. Biophysical and functional assays defined distinct mechanisms: neutralization occurs either by stabilizing the prefusion protein or by preventing the extended intermediate from completing fusion. We also describe a novel mechanism of neutralization in which an antibody prematurely triggers F activation but blocks the subsequent refolding required for viral entry. Together, these findings provide the first detailed mapping of neutralizing epitopes on the MeV F protein and establish a framework for the rational design of F-targeted intervention.

Identifiers

PMID41000703
PMCPMC12458459

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.